The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > OX LDL method for Reverse Cholesterol Transport

OX-LDL method for Reverse cholesterol transport

Innovative and proprietary technique  only available at Physiogenex.
This method will demonstrate if your compound promotes reverse cholesterol transport and has therefore the potential to prevent cardiovascular diseases.

key benefits

  • In-house innovative and validated method.
  • In vivo reverse cholesterol transport using 3H-labeled oxidized LDL-cholesterol is the best approach to evaluate compounds affecting HDL metabolism and reverse cholesterol transport.
  • Essential and robust data to demonstrate that your compound promotes the transport of cholesterol from peripheral tissues to the feces and has therefore the potential to prevent atherosclerosis.

Description and parameters

The ox-LDL method consists in an injection of 3H-cholesteryl oleate labeled/oxidized LDL intravenously.

This proprietary method traces the cholesterol metabolism in vivo and may be useful to evaluate drugs affecting reverse cholesterol transport – RCT.

Species

  • Hamster
  • Mouse
  • Rat
Physiogenex ox LDL method for reverse cholesterol transport
Physiogenex ox LDL method for reverse cholesterol transport

Parameters evaluated

  • Plasma total cholesterol, HDL-c and HDL-c/TC ratio
  • ³H-cholesterol appearance in plasma, HDL, liver, bile and feces

Add-on studies

Fact sheet

oxLDL method Reverse Cholesterol Transport

REFERENCES

Briand F. et al, Arterioscler Thromb Vasc Biol. 2013; 33(1):13-23.
Briand F. et al, Circulation. 2011; 124: A11835.